Corton Capital Inc. Makes New $99,000 Investment in Kura Oncology, Inc. (NASDAQ:KURA)

Corton Capital Inc. bought a new stake in Kura Oncology, Inc. (NASDAQ:KURA) in the fourth quarter, Holdings Channel reports. The institutional investor bought 11,344 shares of the company’s stock, valued at approximately $99,000.

Other hedge funds have also made changes to their positions in the company. Barclays PLC raised its holdings in Kura Oncology by 104.5% during the third quarter. Barclays PLC now owns 165,484 shares of the company’s stock worth $3,234,000 after purchasing an additional 84,563 shares in the last quarter. Franklin Resources Inc. raised its stake in shares of Kura Oncology by 1.5% during the 3rd quarter. Franklin Resources Inc. now owns 1,588,401 shares of the company’s stock worth $28,687,000 after buying an additional 23,113 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Kura Oncology by 0.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 409,241 shares of the company’s stock worth $7,997,000 after buying an additional 3,092 shares in the last quarter. Harbor Capital Advisors Inc. lifted its holdings in shares of Kura Oncology by 4.4% in the 4th quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company’s stock valued at $430,000 after buying an additional 2,076 shares during the period. Finally, SG Americas Securities LLC purchased a new stake in shares of Kura Oncology in the fourth quarter valued at approximately $436,000.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on KURA shares. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of Kura Oncology in a research note on Monday, April 28th. Wedbush reaffirmed an “outperform” rating and issued a $36.00 target price on shares of Kura Oncology in a report on Tuesday, April 8th. StockNews.com lowered Kura Oncology from a “buy” rating to a “hold” rating in a research note on Friday, May 2nd. BTIG Research downgraded Kura Oncology from a “buy” rating to a “neutral” rating in a research note on Thursday, February 6th. Finally, JMP Securities reiterated a “market outperform” rating and set a $28.00 target price on shares of Kura Oncology in a research report on Tuesday, April 29th. Four equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $23.89.

Kura Oncology Price Performance

KURA opened at $6.00 on Friday. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. The company’s 50-day moving average price is $6.60 and its 200 day moving average price is $9.31. Kura Oncology, Inc. has a fifty-two week low of $5.41 and a fifty-two week high of $23.48. The firm has a market cap of $519.45 million, a price-to-earnings ratio of -2.54 and a beta of 0.50.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Thursday, May 1st. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.15). The firm had revenue of $14.11 million for the quarter, compared to the consensus estimate of $39.08 million. As a group, sell-side analysts expect that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.